DK1005332T3 - Farmaceutisk præparat til reduktion af produktion af MCP-1-protein - Google Patents

Farmaceutisk præparat til reduktion af produktion af MCP-1-protein

Info

Publication number
DK1005332T3
DK1005332T3 DK98943862T DK98943862T DK1005332T3 DK 1005332 T3 DK1005332 T3 DK 1005332T3 DK 98943862 T DK98943862 T DK 98943862T DK 98943862 T DK98943862 T DK 98943862T DK 1005332 T3 DK1005332 T3 DK 1005332T3
Authority
DK
Denmark
Prior art keywords
mcp
protein
pharmaceutical composition
reducing production
reducing
Prior art date
Application number
DK98943862T
Other languages
Danish (da)
English (en)
Inventor
Angelo Guglielmotti
Alberto Mantovani
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of DK1005332T3 publication Critical patent/DK1005332T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98943862T 1997-07-28 1998-07-22 Farmaceutisk præparat til reduktion af produktion af MCP-1-protein DK1005332T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004924 WO1999004770A2 (fr) 1997-07-28 1998-07-22 Composition pharmaceutique active dans la reduction de production de proteine mcp-1

Publications (1)

Publication Number Publication Date
DK1005332T3 true DK1005332T3 (da) 2004-02-09

Family

ID=11377642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98943862T DK1005332T3 (da) 1997-07-28 1998-07-22 Farmaceutisk præparat til reduktion af produktion af MCP-1-protein

Country Status (16)

Country Link
US (1) US6534534B1 (fr)
EP (1) EP1005332B1 (fr)
JP (2) JP4651191B2 (fr)
AR (1) AR016382A1 (fr)
AT (1) ATE251902T1 (fr)
AU (1) AU744492B2 (fr)
CA (1) CA2300289C (fr)
DE (1) DE69819012T2 (fr)
DK (1) DK1005332T3 (fr)
ES (1) ES2207858T3 (fr)
HK (1) HK1028561A1 (fr)
IT (1) IT1293795B1 (fr)
PT (1) PT1005332E (fr)
SI (1) SI1005332T1 (fr)
WO (1) WO1999004770A2 (fr)
ZA (1) ZA986636B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
EP3181551A1 (fr) 2008-03-07 2017-06-21 Aziende Chimiche Riunite Angelini Francesco A.C.R. Dérivés de 1-benzyl-3-hydroxymethylindazole et leur utilisation pour traiter les états liés à l'expression du cx3cr1 et du p40
BRPI0907974A2 (pt) * 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
AU2009221063B2 (en) 2008-03-07 2013-03-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, and CX3CR1
ES2480278T3 (es) 2009-08-03 2014-07-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Procedimiento para la preparación de 1-bencil-3-hidroximetil-1H-indazol y sus derivados y productos intermedios de magnesio requeridos
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011106611A2 (fr) 2010-02-25 2011-09-01 Prairie Ventures, L.L.C. Système et procédé de manipulation, de stockage et d'analyse d'échantillons anatomopathologiques
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
EP3307068B1 (fr) 2015-06-12 2021-08-25 Vettore, LLC Inhibiteurs de mct4 pour le traitement de maladies
AU2017375960B2 (en) 2016-12-12 2022-03-10 Vettore, LLC Heterocyclic inhibitors of MCT4
WO2020261158A1 (fr) 2019-06-25 2020-12-30 Translatum Medicus Inc. Procédés de fabrication d'acide 2-((1-benzyl-1h-indazol-3-yl)méthoxy)-2-méthylpropanoïque et de ses dérivés

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
AU5537994A (en) * 1992-10-22 1994-05-09 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Also Published As

Publication number Publication date
SI1005332T1 (en) 2004-02-29
JP2001510793A (ja) 2001-08-07
ITMI971789A1 (it) 1999-01-28
AR016382A1 (es) 2001-07-04
HK1028561A1 (en) 2001-02-23
PT1005332E (pt) 2004-03-31
AU9160198A (en) 1999-02-16
DE69819012D1 (de) 2003-11-20
JP5086322B2 (ja) 2012-11-28
EP1005332A2 (fr) 2000-06-07
WO1999004770A2 (fr) 1999-02-04
IT1293795B1 (it) 1999-03-10
CA2300289C (fr) 2007-11-20
ATE251902T1 (de) 2003-11-15
ZA986636B (en) 1999-02-04
US6534534B1 (en) 2003-03-18
CA2300289A1 (fr) 1999-02-04
WO1999004770A3 (fr) 1999-04-15
AU744492B2 (en) 2002-02-28
JP2010047609A (ja) 2010-03-04
JP4651191B2 (ja) 2011-03-16
ES2207858T3 (es) 2004-06-01
DE69819012T2 (de) 2004-08-12
EP1005332B1 (fr) 2003-10-15

Similar Documents

Publication Publication Date Title
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
PT1066027E (pt) Composicao farmaceutica de topiramato
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
ID27415A (id) Komposisi farmaseutik
ID18663A (id) Komposisi farmasi berlapis enterik
PT981375E (pt) Composicoes farmaceuticas contendo proteinas do plasma
DK1035833T3 (da) Sammensætning til nasal indgivelse
NO20015175L (no) Farmasöytisk sammensetning
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
PT907364E (pt) Composicao farmaceutica de libertacao sustida
ID29262A (id) Komposisi farmasi
DK0911416T3 (da) Fremgangsmåde til fremstilling af protein
ATE260674T1 (de) Stabilisierte proteinzusammensetzung
DK1121116T3 (da) Farmaceutisk præparat af fluvastatin med opretholdt frigivelse
ID27201A (id) Komposisi farmasi
ID21009A (id) Komposisi untuk supositori
DK1005332T3 (da) Farmaceutisk præparat til reduktion af produktion af MCP-1-protein
NO20010089D0 (no) Farmasöytisk levotyroksinpreparat
ID29294A (id) Komposisi farmasi
DE69804218D1 (de) Zementzusammensetzung
ID25857A (id) Komposisi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
ID18698A (id) Komposisi farmasi
ID26215A (id) Komposisi farmasi
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer